ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,770.53
1.01%
US Tech 100
19,690.00
1.28%
Dow Jones
42,153.32
0.86%
Brent Oil
75.22
0.14%
Bitcoin
69,974.02
3.18%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. MacroGenics Inc (MGNX)

  7. MacroGenics Inc (MGNX) News

MacroGenics Inc

MacroGenics Inc (MGNX)

NASDAQ
3.715
0.015
( 0.41% )
Updated: 13:15:41
Delayed by 15 minutes

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Premium

MGNX News

Official News Only

Form 8-K - Current report
Edgar (US Regulatory)
October 30 2024
MGNX (0.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
October 09 2024
MGNX (0.41%)

Form 4 - Statement of changes in beneficial ownership of securities
Edgar (US Regulatory)
September 25 2024
MGNX (0.41%)

Form 8-K - Current report
Edgar (US Regulatory)
September 16 2024
MGNX (0.41%)

MGNX Discussion

View Posts
Monksdream Monksdream 1 month ago
MGNX new 52 week low
👍️0
Monksdream Monksdream 1 month ago
MGNX new 52 week low
👍️0
Money Management Money Management 5 months ago
Lucy runs
👍️0
Dubster watching Dubster watching 6 months ago
Blessings sir!
👍️0
Tom turtles Tom turtles 6 months ago
Well, I never got in. Thought it might of seen upper twos today. Watched it go up 30% though. Got in AMC for some reason. Glad someone made some money here.
👍️0
Dubster watching Dubster watching 6 months ago
I thought I was going to take a loss on my bottom feeding expedition, but instead I am thankful that He blesses me!
👍️0
Dubster watching Dubster watching 6 months ago
Bingo
👍️0
Dubster watching Dubster watching 6 months ago
Finally sold some greened up.
I wait until the issues aren’t deaths
👍️0
Tom turtles Tom turtles 6 months ago
$2.50 Monday ?
👍️0
Dubster watching Dubster watching 6 months ago
These guys are getting hammered! 75%
👍️0
Dubster watching Dubster watching 6 months ago
Down 75% this should be wild today!
👍️0
Dubster watching Dubster watching 6 months ago
Took a starter, gotta gave a bounce here.
👍️0
Dubster watching Dubster watching 6 months ago
Interesting drop today.
Hunting
👍️0
stocksrising stocksrising 6 months ago
I’m with ya on entry..planning on a $3ish handle which equals cash on balance sheet( ~ $185mm ish)…. Will do starter in low $4’s(minor $$, then DCA if $3’s ( much more $) …back up truck if deaths not related to clinical’s after internal investigation)
👍️0
Tom turtles Tom turtles 6 months ago
Well, 5 fatalities ready didn't help...geez...Looking for entry
👍️0
Monksdream Monksdream 8 months ago
MGNX new 52 week high
👍️0
Monksdream Monksdream 8 months ago
MGNX new 52 week high
👍️0
Monksdream Monksdream 9 months ago
MGNX new 52 week high
K
👍️0
Monksdream Monksdream 9 months ago
MGNX new 52 week high
👍️0
Monksdream Monksdream 9 months ago
MGNX
👍️0
Monksdream Monksdream 10 months ago
MGNX new 52 week high
👍️0
Monksdream Monksdream 10 months ago
MGNX new 52 week high
👍️0
ipo_dude ipo_dude 10 months ago
Lets do this . Can it keep going
👍️0
MiamiGent MiamiGent 11 months ago
MGNX $10.71 +1.48 (+16.03%)
Nice steady climb, as shorts writhe and wail
👍️0
MiamiGent MiamiGent 11 months ago
MGNX I'm going with this
$10.50 +1.27 (+13.76%)
It's a bit of a bail, as I have other work to catch up on
Squeeze of 13% short, on a Citi upgrade to $13

Could turn into a several days hold, for incremental gains. Maybe 5% more today??

https://stockcharts.com/h-sc/ui?s=MGNX

Citigroup Upgrades Macrogenics to Buy, Raises Price Target to $13
BENZINGA 4:20 AM ET Dec-20-2023

Citigroup analyst Yigal Nochomovitz upgrades Macrogenics (MGNX.NaE) from Neutral to Buy and raises the price target from $7 to $13.


Company Profile
SectorHealth CareOpens in a new window
IndustryBiotechnologyOpens in a new window
Company LocationRockville, MD
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 x CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, i
👍️0
ipo_dude ipo_dude 11 months ago
👀
👍️0
ipo_dude ipo_dude 11 months ago
Shes ready to pop above $10
👍️0
XenaLives XenaLives 2 years ago
Historic short interest:

You can go to this link to check short interest in a stock:
http://nasdaqtrader.com/Trader.aspx?id=ShortInterest

Publication schedule is here:
http://nasdaqtrader.com/Trader.aspx?id=ShortIntPubSch


Settlement Date/Short Interest/Percent Change/
Average Daily Share Volume/Days to Cover

01/13/2023 4,373,837 5.28 507,089 8.63
12/30/2022 4,154,346 7.91 575,736 7.22
12/15/2022 3,849,672 (5.66) 633,050 6.08
11/30/2022 4,080,607 (4.36) 1,384,683 2.95
11/15/2022 4,266,434 (15.78) 1,093,099 3.90
10/31/2022 5,065,570 2.50 1,487,531 3.41
10/14/2022 4,942,015 (0.29) 379,450 13.02
09/30/2022 4,956,490 1.85 563,681 8.79
09/15/2022 4,866,500 (0.81) 635,807 7.65
08/31/2022 4,905,995 (13.08) 631,036 7.77
08/15/2022 5,644,366 (0.09) 971,172 5.81
07/29/2022 5,649,639 (17.42) 1,065,799 5.30
07/15/2022 6,841,233 (10.73) 1,407,012 4.86
06/30/2022 7,663,135 (0.99) 2,692,200 2.85
06/15/2022 7,739,527 27.13 1,239,553 6.24
05/31/2022 6,088,004 8.28 827,523 7.36
05/13/2022 5,622,390 10.78 1,337,461 4.20
04/29/2022 5,075,315 3.20 453,486 11.19
04/14/2022 4,917,910 (4.48) 509,771 9.65
03/31/2022 5,148,635 3.46 522,723 9.85
03/15/2022 4,976,392 36.20 868,105 5.73
02/28/2022 3,653,830 4.57 898,618 4.07
02/15/2022 3,494,052 19.83 571,075 6.12
01/31/2022 2,915,828 7.17 457,915 6.37
👍️0
XenaLives XenaLives 2 years ago
So what exactly did MGNX do to this diabetes drug?


MacroGenics to get $60M milestone from Provention as FDA approves diabetes drug Tzield


More homework:
https://patents.justia.com/assignee/macrogenics-inc
👍️0
XenaLives XenaLives 2 years ago
Looking at MGNX because the chart is intriguing..

VBP is consolidating nicely...

👍️0
XenaLives XenaLives 2 years ago
Now I need to figure out what DART and TRIDENT are...


Nov 17, 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement.

“We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes.”

Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product.

Based on MacroGenics’ cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.


http://ir.macrogenics.com/news-releases/news-release-details/macrogenics-and-zai-lab-enter-broad-strategic-collaboration
👍️0
XenaLives XenaLives 2 years ago
Nov 17, 2022
MacroGenics Earns $60 Million Milestone with U.S. FDA Approval of Teplizumab
ROCKVILLE, MD, Nov. 17, 2022 (GLOBE NEWSWIRE) --

MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today reported that the U.S. Food and Drug Administration announced the approval of the Biologics License Application (BLA) for teplizumab, an anti-CD3 monoclonal antibody that was previously developed by MacroGenics. Teplizumab was acquired by Provention Bio, Inc. in May 2018 pursuant to an asset purchase agreement.

“We are very pleased to see the culmination of years of effort by Provention, MacroGenics, and tireless champions in academia and government, with the achievement of the approval of teplizumab,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “We applaud this outcome, which represents an advancement for individuals and their families dealing with the risks and consequences of type 1 diabetes.”

Under the agreement, Provention is obligated to pay MacroGenics contingent milestone payments totaling $170 million upon the achievement of certain regulatory approval milestones, including $60 million for the approval of a BLA for a first indication in the United States. In addition, Provention is obligated to make contingent milestone payments to MacroGenics totaling $225 million upon the achievement of certain sales milestones as well as a single-digit royalty on net sales of the product.

Based on MacroGenics’ cash, cash equivalents and marketable securities balance as of September 30, 2022, plus projected and anticipated payments from partners, including timely receipt of the milestone payment from Provention, MacroGenics currently anticipates having a cash runway into late 2024.

https://www.globenewswire.com/news-release/2022/11/17/2558767/0/en/MacroGenics-Earns-60-Million-Milestone-with-U-S-FDA-Approval-of-Teplizumab.html
👍️0
makinezmoney makinezmoney 2 years ago
$MGNX: What did I tell ya........ hit $4.15 !!!!!!!!!


MUAHHHHhhhhhhhhhh ha ha ha ha ha haaaaaaaaaAAAAAAAAAAAAAA



LOVE IT when a plan comes together like that


Looking for more winners............ stand by


GO $MGNX
👍️0
makinezmoney makinezmoney 2 years ago
$MGNX: Perfeccccccttttttttt Cup & Handle here at 3.50


Added 10k shares here


Get to $4 !!!!!!!!


GOO $MGNX
👍️0
ipo_dude ipo_dude 4 years ago
Where do we go from here?
👍️0
Now516 Now516 4 years ago
FDA approval: https://www.macrogenics.com/news/macrogenics-announces-fda-approval-of-margenza-for-patients-with-pretreated-metastatic-her2-positive-breast-cancer/
👍️0
Glider549 Glider549 4 years ago
https://biopharmcatalyst.us13.list-manage.com/track/click?u=ce642b003b32103d28995373d&id=a988dba9aa&e=d1924831d6
👍️0
rsconcept rsconcept 4 years ago
SCAM ALERT, be careful the SEC must be looking at it as we speak.
This is a $13-$16 stock at best.
👍️0
rsconcept rsconcept 4 years ago
https://newsnation1.com/macrogenics-inc-mgnx-scam-news/
👍️0
ClayTrader ClayTrader 4 years ago
* * $MGNX Video Chart 05-11-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
Hercules1 Hercules1 4 years ago
$MGNX:

Nice to see shorts getting killed here.

Go ahead short some more you cowards.
👍️0
ClayTrader ClayTrader 4 years ago
* * $MGNX Video Chart 05-07-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
davidsson10 davidsson10 5 years ago
+$$$ MGNX

Successful lifestyle enhancement trading.....
👍️0
ClayTrader ClayTrader 5 years ago
* * $MGNX Video Chart 05-06-2020 * *

Link to Video - click here to watch the technical chart video

👍️0
rsconcept rsconcept 5 years ago
great, lets short it again!
👍️0
crudeoil24 crudeoil24 5 years ago
Investors are forward looking, especially into company pipeline.
👍️0
PAC PAC 5 years ago
What i say? Retest after shakeout 19s
👍️0
crudeoil24 crudeoil24 5 years ago
We all ran with this from earlier today. Shorts will have their cluster rama rally now. GLTY.
👍️0
godofthestock godofthestock 5 years ago
TIMBER!!!!!!!


IMO
👍️0
godofthestock godofthestock 5 years ago
This is going to be great IMO
👍️0

Your Recent History

NASDAQ
MGNX
MacroGenics
LSE
BB49
Citi Fun 33
TG
BLB8DT
BayernLB
EU
VDPBN
Ville de Paris 1.46% 17s...
TG
CZ439N
Commerzbank
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved